A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer

Anticancer Research

Volumn 27, Issue 1 B, 2007, Pages 681-685

  Mouratidou, D ^a   Gennatas, C ^b   Michalaki, V ^b   Papadimitriou, A ^c   Andreadis, Ch ^a   Sykiotis, C ^b   Tsavaris, N ^d  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Nikea General Hospital Athens   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cyclophosphamide; Ovarian cancer; Paclitaxel

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL;

ALOPECIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME; VOMITING;

EID: 33847756722     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Randall TC and Rubin SC: Cytoreductive surgery for ovarian cancer. Surg Clin North Am 81: 871-883, 2001.
2. Gonzalez-Martin AJ: Medical treatment of epithelial ovarian cancer. Expert Rev Anticancer Ther 6: 1125-1143, 2004.
3. Ozols RF: Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. Cancer Invest Suppl 2: 11-20, 2004.
4. Muggia FM: Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin Oncol, Suppl 14: 17-24, 2004.
5. Thigpen JT, Blessing JA, Ball H et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12: 1748-1753, 1994.
6. ICON and EORTC-ACTION investigators: International Collaboration on Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian cancer. J Natl Cancer Inst 95: 105-112, 2003.
7. Mc Guire WP, Hoskins WJ, Brady MF et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
8. Piccart MJ, Bertelsen, James K et al: Randomized Intergroup Trial of cisplatin-placlitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000.
9. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
10. Cox DR: Regression models and life-tables. J R Stat Soc B34: 187-202, 1972.
11. Sandercock J, Parmar MK, Torri V et al: First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 8: 815-824, 2002.
12. Harries M and Gore M: Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 9: 529-536, 2002.
13. ICON and AGO collaborators: Paclitaxel plus platinum based chemotherapy versus conventional platinum based chemotherapy in women with relapsed ovarian cacer: The ICON4/AGO-OVAR 2.2 trial. Lancet 361: 2099-2106, 2003.
14. Rustin GJ, Timmers P, Nelstrop A et al: Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. Clin Oncol 1: 45-51, 2006.
15. Stuart G, Bertelsen K, Mangioni C et al: Updated analysis shows a highly significant overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-NOCOVA-NCI-C and Scottish intergroup trial. Proc Am Soc Clin Oncol 17: 361A, (abstr 1394), 1998.
16. International Collaborative on Ovarian Neoplasm (ICON) Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomized trial. Lancet 360: 505-515, 2002.
17. Muggia FM, Braly PS, Brady MF et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 1: 106-115, 2000.
18. Ozols RF, Bundy BN, Greer BE et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 17: 3194-3200, 2003.
19. Piccart MJ, Bertelsen K, Stuart G et al: Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13(Suppl 2): 144-148, 2003.